<p>Deep vein thrombosis (DVT) is a prevalent thrombotic condition affecting a wide range of patients, including post-partum women, immobilized individuals, and those who have undergone surgery, suffered heavy trauma, or had malignancies. Given the high incidence of the disease, identifying molecular and genetic tools that can predict, indicate prognosis, and serve as therapeutic targets would be a significant advancement in clinical practice for a broad spectrum of patients. However, traditional treatments often face challenges, leading to post-thrombotic syndrome (PTS) development in complex cases. Non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have demonstrated essential regulatory roles in cellular pathways and have been found to be dysregulated in DVT patients and animal models. This knowledge provides new insights into the pathophysiology of DVT and paves the way for utilizing ncRNAs as diagnostic, predictive, and prognostic indicators, as well as therapeutic targets. Recent advancements have led to significant recanalization of thrombosed veins in animal models. In this review, we delve into the current literature on ncRNAs in DVT to highlight their potential for understanding disease mechanisms and improving patient outcomes.</p> Graphical abstract <p>This figure illustrates the role of non-coding RNAs (ncRNAs) in the pathophysiology of deep vein thrombosis (DVT) and their potential use as clinical biomarkers for diagnosis, prediction, and prognosis of DVT in patients. Data used for figure design have been cited in the text.</p> <p></p>